Striving to advance Alzheimer's disease drug development, the US FDA has revised its draft guidance to give sponsors more leeway in trial designs.
Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance
US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.
